Drug intelligence / Profile preview

rapcabtagene autoleucel (Novartis)

Development stage: Unknown
Lead developer: Novartis
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

Rapcabtagene autoleucel (PHE885) is an autologous, second-generation chimeric antigen receptor (CAR) T-cell therapy targeting the B-cell maturation antigen (BCMA). Developed by Novartis, it is manufactured using the proprietary T-Charge platform, which significantly reduces the ex vivo culture time to less than two days. This rapid manufacturing process is designed to preserve T-cell stemness and potentially enhance in vivo expansion and persistence. The drug is primarily being investigated for the treatment of relapsed or refractory multiple myeloma.

Other names: rap-celrapcabtagene autoleucel

Targets

BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on rapcabtagene autoleucel (Novartis).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rapcabtagene autoleucel (Novartis).

Explore the full profile